Showing results (101-110 of 163) with videos related to

Sort By:
Pageof 17
Oncology|August 30, 2019
Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 30, 2019
Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: A multicenter analysis with propensity score matchingToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Hepato-Gastroenterology|May 21, 2009
Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolizationAtsushi Hiraoka, Norio Horiike, Yoshimasa Yamashita, et al.
Cancer Medicine|May 26, 2019
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions-Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
Medcomm|November 4, 2024
Prognostic impact of age on outcomes of hepatic decompensation in patients with compensated cirrhosis (CHESS2102): an international, multicenter cohort studyShanghao Liu, Jia Li, Yujun Wong, et al.
Liver Cancer|February 20, 2020
Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with LenvatinibAtsushi Hiraoka, Takashi Kumada, Shinya Fukunishi, et al.
Oncology|July 16, 2019
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular CarcinomaAtsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, et al.
The American Journal of Gastroenterology|August 16, 2022
A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort StudyChuan Liu, Zhujun Cao, Huadong Yan, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|February 18, 2020
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinibToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
European Journal of Gastroenterology & Hepatology|April 14, 2020
Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Pageof 17